ArticleFrontiers in oncology2026
Glofitamab in the sequential treatment of relapsed/refractory B-Cell lymphoma: a single-center real-world study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glofitamab is a bispecific antibody (BsAb), and has good efficacy in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL), especially in relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). This study explored its sequential treatment strategies and efficacy in the real world, including rescue therapy after chimeric antigen receptor T cell (CAR-T) therapy failure, bridging CAR-T therapy and monotherapy. Methods: This was a single-center retrospective cohort analysis of 24 patients with clearly diagnosed relapsed/refractory B-cell lymphoma, including primary diffuse large B-cell lymphoma (DLBCL), diffuse large B-cell lymphoma with Richter transformation (DLBCL-RT), and Burkitt lymphoma (BL). Patients were divided into three groups according to the treatment sequence: Group 1 (Glofitamab rescue therapy after progression of CAR-T therapy), group 2 (Glofitamab bridging subsequent CAR-T therapy), and group 3 (Glofitamab monotherapy), who received Glofitamab at our center between September 2024 and December 2025. Conclusions: In the single-center real-world experience, Glofitamab demonstrated controllable safety and durable anti-tumor activity in three clinical scenarios. Especially, it could still bring clinical benefits even after CAR-T therapy failed, and it explored the sequential treatment strategy of Glofitamab and CAR-T.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.